AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01924065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Anticoagulant
Description: warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
Study NCT03165981 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: ACIP Recommended vaccine
Study NCT03165981 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP
Description: ACIP Recommended vaccine
Study NCT03165981 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IIV
Description: ACIP Recommended vaccine
Study NCT02299869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Azul (Competitor-control)
Description: contact lens
Study NCT02299869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Blue (CVI-test)
Description: contact lens
Study NCT01245777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose
Description: 20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
Study NCT04370236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INB03
Description: Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
Study NCT02898740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural exercise
Description: Exercise instruction and encouragement
Study NCT02898740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Provision of general information about a variety of health topics
Study NCT04210544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental dietary protein
Description: Breakfast intake consisted on a 250 g custard intake mixed with 20 g of the experimental protein accompanied by a glass with 50 mL water.
Study NCT04210544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Description: Breakfast intake consisted on a 250 g custard intake mixed with 20 g of casein accompanied by a glass with 50 mL water.
Study NCT04210544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Breakfast intake consisted on a 250 g custard intake mixed with 20 g of water accompanied by a glass with 50 mL water.
Study NCT01968031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg
Description: Istradefylline 40 mg and placebo
Study NCT01968031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg
Description: Istradefylline 20 mg and placebo
Study NCT01968031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01968031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00563394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ofloxacin
Description: 400 mg twice a day for 14 days
Study NCT00563394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSI-78
Description: 1%/2% topical cream twice a day for 14 days
Study NCT02218216 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI Diagnostic
Description: Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
Study NCT02218216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Diagnostic
Description: Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
Study NCT02921516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N'ap Grandi
Description: Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
Study NCT02921516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: N'ap Grandi - A
Description: Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
Study NCT02921516 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Promotion - A
Description: Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
Study NCT02151149 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nab-paclitaxel
Study NCT04370236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive up to two once per week subcutaneous injections of Placebo
Study NCT02151149 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Study NCT02893540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: we are going to compare two maintenance treatment models with capecitabine in this study
Study NCT02893540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: we are going to compare two maintenance treatment models with capecitabine in this study
Study NCT02233751 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate auto-injector
Description: Randomization then administration of combination product study medication according to group assignment
Study NCT03345615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 30-day ambulatory cardiac event monitor
Description: SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
Study NCT02484508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guli capsule
Description: Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
Study NCT02484508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kangguzengsheng capsule
Description: Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
Study NCT02627001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuMask Intraoral Airway Device
Description: NuMask Intraoral Airway Device
Study NCT02627001 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bag Valve Mask
Description: Conventional bag valve mask
Study NCT04537520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerecis Omega3 Wound
Description: Treatment of the wound with Kerecis Omega3 Wounds matrices
Study NCT03710551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
Study NCT03710551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Infant Formula
Description: Standard bovine milk-based infant formula, fed ad libitum
Study NCT02002130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo GABA and Placebo GAD-alum
Description: Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
Study NCT02002130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GABA and Placebo GAD-alum
Description: Oral Active GABA with Placebo GAD-alum
Study NCT02002130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Oral GABA and Active GAD-alum injection
Description: Active Oral GABA and Active GAD-alum injection
Study NCT03914898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse led intervention group
Description: This program is based on cognitive restructuring tecniques.
Study NCT00475410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCs (Cx401, company code)
Description: Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then.
Study NCT00475410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive
Description: Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
Study NCT00475410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin adhesive
Description: Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
Study NCT01080820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX157
Description: One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
Study NCT01080820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
Study NCT01080820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread
Description: One single oral dose of 300mg Viread.
Study NCT01080820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viread
Description: One single oral dose of 300mg Viread.
Study NCT01080820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread
Description: One single oral dose of 300mg Viread.
Study NCT00198133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premetrexed (Alimta)
Description: Pemetrexed will be 500 mg/m2 IV every 3 weeks
Study NCT00160524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CDP870)
Description: Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
Study NCT03425019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix 1x1 tDCS mini-CT Stimulator device
Description: Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
Study NCT03291795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Study patients will undergo a program of prehabilitation exercise for 6 days per week prescribed for them by an exercise physiologist, for up to 4 weeks prior to surgery.
Study NCT02518906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Identity Treatment
Description: Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013.
Study NCT02518906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-A
Description: Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
Study NCT01342653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC
Description: see Design
Study NCT02980679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTC
Description: After injection of CTC, a whole body and thyroid scan will be performed.
Study NCT02980679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-PERT
Description: After injection of G-PERT, a whole body and thyroid scan will be performed.
Study NCT02537444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Study NCT02537444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib and pembrolizumab combination
Study NCT04185610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qi Gong
Description: Guided Qi Gong class
Study NCT02627846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVLA
Description: 1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
Study NCT02627846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClariVein®
Description: 1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
Study NCT02627846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with 1:200,000 epinephrine solution
Description: It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
Study NCT02627846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with 1:200,000 epinephrine solution
Description: 100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
Study NCT02627846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: 10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
Study NCT02627846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Tetradecyl Sulphate
Description: 1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
Study NCT03306069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
Study NCT03306069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).~HIIT:~* 2 sessions per week~* 5x1 min at 80-95% HRmax~* time-effort per week: \~30 min
Study NCT03306069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIIT-HR
Description: Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).~MIIT-HR:~* 2 sessions per week~* 5x1 min at 65-79% HRmax~* time-effort per week: \~30 min
Study NCT03306069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIIT-LT
Description: Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).~MIIT-LT:~* 2 sessions per week~* session 1: 2x4 min / session 2: 5x1 min, each at 105% LT~* time-effort per week: \~30 min
Study NCT02341014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .
Study NCT02341014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Study NCT02341014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02807454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Study NCT02807454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study NCT02807454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT02807454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT04490668 — intervention group
Intervention type: BIOLOGICAL
Intervention: Human albumin
Description: Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
Study NCT01772342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA filtration
Description: Night time air purification with the PureNight air purification system with the HEPA filter in place
Study NCT01772342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Night time air purification with the PureNight air purification system with the HEPA filter removed
Study NCT01074411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IP
Study NCT01074411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IP
Study NCT01074411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01074411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02222727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
Study NCT03774745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone 200 MG
Description: All subjects receive mifepristone tablet on treatment day 1.
Study NCT03774745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 MG
Description: All subjects receive mifepristone tablet on treatment day 1.
Study NCT03774745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized Progesterone
Description: Subjects randomized to progesterone receive treatment starting day 2.
Study NCT03774745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Subjects randomized to placebo receive treatment starting day 2.
Study NCT02009137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVERA
Description: EVERA apply for 12 weeks
Study NCT02009137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESTES
Description: ESTES apply for 12 weeks
Study NCT02350894 — intervention group
Intervention type: BEHAVIORAL
Intervention: Graded and behavevial theraphy
Description: Graded and behavevial theraphy
Study NCT01025180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Procalcitonin level
Description: The duration of antibiotic treatment is based on PCT level:~* \< 0.25 ng/ml: antibiotic should be stopped~* 0.25 \< PCT \<0.5: antibiotic prescription is not recommended~* > 0.5 ng/ml: antibiotic should be used
Study NCT01247818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (0.002% Rose Bengal)
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study NCT01247818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (0.005% Rose Bengal)
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study NCT01247818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (0.01% Rose Bengal)
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study NCT01247818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study NCT02742649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination
Description: Continuous elution from the ocular insert.
Study NCT02742649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Continuous elution from the ocular insert. This is an active control arm.